

Supplementary Table S5. X-chromosomal differentially methylated CpG sites (DMCs) in the discovery cohort ($p < 1.3 \times 10^{-7}$, $\Delta\beta > |0.05|$, $n=31$) and replication cohort analysing female patients with SLE and female controls. Replication criteria were $p < 6.6 \times 10^{-6}$ ($\alpha=0.05$ divided by 7,625 tests) and same direction of effect. P-values for sites that did not replicate are indicated in italics.

Chr	Position	CpG site	Gene	Discovery*		Replication†	
				p Value	Methylation $\Delta\beta$	p Value	Methylation $\Delta\beta$
X	65259910	cg12124912	<i>VSIG4</i>	7.6E-108	-0.072	3.39E-27	-0.043
X	152680754	cg21283832	<i>Intergenic</i>	2.4E-99	-0.087	2E-22	-0.048
X	130964931	cg03073000	<i>LOC286467</i>	3.56E-76	-0.065	2.23E-21	-0.040
X	73163537	cg05836475	<i>LOC554203</i>	6.64E-70	-0.084	3.1E-19	-0.056
X	65238737	cg13716034	<i>MIR223</i>	8.25E-68	-0.064	2.72E-27	-0.050
X	130965143	cg11322877	<i>LOC286467</i>	1.79E-66	-0.081	2.93E-10	-0.032
X	65238616	cg19127840	<i>MIR223</i>	7.27E-66	-0.056	9.45E-10	-0.030
X	73163626	cg24530587	<i>LOC554203</i>	2.28E-61	-0.068	3.81E-31	-0.053
X	53310810	cg00822998	<i>IQSEC2</i>	7.19E-60	-0.066	5.78E-15	-0.035
X	118822815	cg08119631	<i>SEPT6</i>	2.88E-59	0.067	1.37E-19	0.048
X	65238507	cg06701191	<i>MIR223</i>	6.79E-57	-0.056	1.74E-14	-0.031
X	40435744	cg17828255	<i>Intergenic</i>	2.17E-48	-0.051	8.69E-18	-0.041
X	15874162	cg24350752	<i>AP1S2</i>	6.6E-45	-0.064	2.56E-06	-0.032
X	21874808	cg01378112	<i>YY2</i>	3.52E-41	-0.051	3.37E-15	-0.037
X	118536722	cg19753067	<i>SLC25A43</i>	6.35E-41	-0.052	9.93E-17	-0.045
X	123480277	cg10573235	<i>SH2D1A</i>	6.42E-38	0.054	7.35E-24	0.047
X	40009864	cg08156775	<i>BCOR</i>	2.21E-37	-0.062	1.19E-09	-0.041
X	40004346	cg08384999	<i>BCOR</i>	1.78E-36	-0.053	<i>0.000157</i>	-0.019
X	40038858	cg19502998	<i>Intergenic</i>	2.77E-34	-0.051	5.47E-18	-0.043
X	40007949	cg17281810	<i>BCOR</i>	1.29E-32	-0.058	3.93E-07	-0.028
X	49026774	cg25377867	<i>PLP2</i>	1.69E-31	-0.053	2.07E-08	-0.030
X	54946801	cg23213278	<i>TRO</i>	1.29E-27	0.055	2.7E-13	0.044
X	18446221	cg01283227	<i>CDKL5</i>	2.67E-25	-0.051	<i>0.003365</i>	-0.021
X	18446114	cg21771569	<i>CDKL5</i>	3.02E-25	-0.052	5.76E-06	-0.030
X	153094332	cg06616051	<i>PDZD4</i>	8.47E-24	-0.052	1.85E-08	-0.036
X	40009982	cg10055320	<i>BCOR</i>	7.01E-22	-0.060	6.18E-06	-0.038
X	16171477	cg27262852	<i>GRPR</i>	9.4E-21	0.051	7.46E-39	0.077
X	73515285	cg19847571	<i>Intergenic</i>	1.42E-19	0.052	7.26E-35	0.079
X	12940308	cg20981403	<i>TLR8</i>	3.07E-19	0.052	1.09E-33	0.086
X	40016611	cg01110765	<i>BCOR</i>	7.63E-16	-0.064	<i>1.91E-05</i>	-0.042
X	39864206	cg06008640	<i>Intergenic</i>	3.46E-15	-0.051	<i>0.002482</i>	-0.025

*The discovery cohort included 300 female SLE patients and 351 female control individuals.

† The replication cohort included 175 female SLE patients and 174 female control individuals.